S. Kendall

发表

Molecular characterization of breast cancer cell lines through multiple omic approaches

Frederick S. Vizeacoumar, Franco J. Vizeacoumar, F. Vizeacoumar, 2017, Breast Cancer Research.

Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel

Frederick S. Vizeacoumar, Franco J. Vizeacoumar, F. Vizeacoumar, 2022, Scientific Reports.

Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells

S. Adam, P. M. Campbell, C. Der, 2006, Current Biology.

Genetically Engineered Human Cancer Models Utilizing Mammalian Transgene Expression

S. Adam, C. Counter, S. Kendall, 2006, Cell cycle.

Molecular characterization of breast cancer cell lines through multiple omic approaches

F. Vizeacoumar, F. Vizeacoumar, S. Napper, 2017, Breast cancer research : BCR.

Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers

F. Vizeacoumar, F. Vizeacoumar, Sabuj Sarker, 2016, Breast Cancer Research.

Targeting eNOS in pancreatic cancer.

B. Ancrile, David F. Kashatus, C. Counter, 2012, Cancer research.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis

Deborah H. Anderson, A. Saxena, P. Mellor, 2022, PloS one.

Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers

F. Vizeacoumar, F. Vizeacoumar, Sabuj Sarker, 2016, Breast Cancer Research.

A network of genetic events sufficient to convert normal human cells to a tumorigenic state.

S. Adam, C. Counter, C. Linardic, 2005, Cancer research.

Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).

Jeffrey A Jones, I. Flinn, Jennifer R. Brown, 2015 .